Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 118

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 118
---
 million in 2024, down from $46.1 million in 2023, impacted by the launch and NRDL inclusion of competing same-class MET TKIs in China. Our consolidated revenue was $24.5 million, down 15% from last year of $28.9 million.

In 2021, 2022 and the first two months of 2023, Orpathys was sold as a self-pay drug. Following negotiations with the NHSA in January 2023, Orpathys were included in the updated NRDL at a 38% discount relative to the self-pay price, broadening patient access to this medicine. Following the contract renewal with the NHSA, the updated NRDL effective on January 1, 2025 will continue to include Orpathys at the same price as the 2023-24 NRDL price.

In March 2023, Orpathys was approved in the Macau Special Administrative Region. In February 2025, it was approved in Hong Kong Special Administrative Region under the“1+” mechanism.

Surufatinib (Sulanda in China)

Surufatinib was approved in China for non-pancreatic NETs in December 2020 and for pancreatic NETs in June 2021. It is being marketed by us in China under the brand name Sulanda. There are approximately 34,000 new patients per year in China. According to IQVIA tracking study report in the fourth quarter of 2023, Sulanda maintained its position in the market with 21% prescription share in NET treatment, ahead of competitors Sutent and Afinitor. Sulanda is also being investigated in a Phase II/III trial in a combination of surufatinib, camrelizumab (PD-1 antibody), nab-paclitaxel and gemcitabine for 1L PDAC.

Total in-market sales and consolidated revenue in 2024 increased by 11% to $49.0 million (2023: $43.9 million). Surufatinib has been successfully recommended in 2023 Chinese medical association consensus for standardized diagnosis and treatment of pancreatic cancer neuroendocrine neoplasms and four other treatment guidelines for neuroendocrine tumors. Following negotiations with the NHSA, Sulanda continues to be included in the NRDL starting in January 2024 at the same price with 2022-23 NRDL price. We currently own all rights to surufatinib worldwide.

Table of